^
Association details:
Biomarker:No biomarker
Cancer:Non Small Cell Lung Cancer
Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Excerpt:
Bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.
Secondary therapy:
Chemotherapy
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Non-Small Cell Lung Cancer: Useful in Certain Circumstances...Bevacizumab/carboplatin/pemetrexed...Bevacizumab/cisplatin/pemetrexed....Bevacizumab/carboplatin/paclitaxel...
Secondary therapy:
carboplatin + paclitaxel; cisplatin + pemetrexed; carboplatin + pemetrexed